New York Times, Drug Store News
The Food and Drug Administration rejected its third weight-loss drug this month, Qnexa, which is manufactured by Vivus and is a combination of two existing drugs -- phentermine, a stimulant that is approved for short-term use as a weight loss drug, and topiramate, an epilepsy and migraine drug, Andrew Pollack reports.
Vivus says that the FDA has asked for a thorough evaluation of the drug's potential for causing birth defects and heart problems. "It looks pretty bleak out there for anyone trying to get a drug approval for weight loss," says Dr. Ken Fujioka, director of …